Skip to main content

Table 3 SdHR for receiving systemic parenteral treatment considering death as a competing event among the population (n = 633)

From: Impact of polypharmacy and comorbidity on survival and systemic parenteral treatment administration in a cohort of hospitalized lung-cancer patients

 

Univariable analysis

Multivariable analysis*

 

sdHR

CI95

P-value

sdHR

CI95

P-value

Elixhauser

     

< 0 < x ≤ 5

1

  

1

  

6 ≤ x ≤ 11

0.8

0.6-1.0

0.08

0.8

0.7–1.1

0.19

> 11

0.4

0.3–0.6

< 0.01

0.4

0.3–0.6

< 0.01

Polypharmacy

1.3

1.0-1.6

0.06

1.2

1.0-1.6

0.10

  1. Quantitative variables are expressed as medians [Interquartile range]
  2. *Adjusted for the presence of metastasis, gender, and histological type
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us